Immunovant 股票：風險報酬比極具吸引力，給予「投機性買入」初始評級 (IMVT)
· seekingalpha.com
初始給予 Immunovant (IMVT)「買入」評級，目標價 50 美元，主因是 IMVT-1402 具備同類最佳的 IgG 降低效果，且預計銷售額高峰將達到約 40 億美元。
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...